Back

Digoxin improves systolic cardiac function in patients with AF and HFpEF: the RATE-AF randomised trial

29 August 2022 (14:56 - 15:15)
Organised by:
Congress Presentation Part of: How to treat HFpEF in 2022 and beyond Heart Failure with Preserved Ejection Fraction (HFpEF) ESC Professional Premium Access ESC Congress 2022

About the speaker

Photo
Doctor Karina V Bunting

University of Birmingham, Birmingham (United Kingdom of Great Britain & Northern Ireland)

3 More presentations in this session

Presentation thumbnail
Treating HFpEF: State of the art 2022
Professor S. Solomon (Boston, US)
Slides Video
Presentation thumbnail
Efficacy of empagliflozin in patients with heart failure according to baseline KDIGO risk categories - findings from the EMPEROR-Pooled
Professor J. Butler (Dallas, US)
Abstract Slides Video
Presentation thumbnail
Efficacy and safety of sacubitril/valsartan according to frailty in heart failure with preserved ejection fraction: a post hoc analysis of the PARAGON-HF trial
Doctor J. Butt (Copenhagen, DK)
Abstract Slides Video

Access the full session

Session thumbnail
How to treat HFpEF in 2022 and beyond
Video

The Event

Event poster

ESC Congress 2022

29 August 2022 14:56 CET
You may be interested in
thumbnail
Congress Presentation
Interactions of circulating, digoxin-like, steroids with rate control therapy for atrial fibrillation in the RATE-AF randomised clinical trial
thumbnail
Congress Presentation
Utilization and safety of digoxin in patients with chronic heart failure and atrial fibrillation with rapid ventricular rate
thumbnail
Congress Presentation
DIG-META: Digoxin in heart failure and atrial fibrillation

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources